NISSUI PHARMACEUTICAL CO., LTD. Note:This document is a translation of a part of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.
Consolidated Financial Results
for the Three Months Ended June 30, 2022
[Japanese GAAP]
July 27, 2022 | |
Company name: Nissui Pharmaceutical Co.,Ltd. | |
Stock exchange listing: Tokyo | |
Code number: 4550 | |
URL: https://www.nissui-pharm.co.jp | |
Representative: Tokuya Ono | President |
Contact: Tatsuo Ishii | Board Member, CFO Executive Officer |
Phone: 03-5846-5611
Scheduled date of filing quarterly securities report: August 05, 2022
Scheduled date of commencing dividend payments: -
Availability of supplementary briefing material on quarterly financial results: No
Schedule of quarterly financial results briefing session: No
(Amounts of less than one million yen are rounded down)
1. Consolidated Financial Results for the Three Months Ended June 30, 2022 (April 01, 2022 to June 30, 2022)
(1) Consolidated Operating Results | (% indicates changes from the previous corresponding period.) | ||||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | ||||||||
owners of parent | |||||||||||
Three months ended | Million yen | % | Million yen | % | Million yen | % | Million yen | % | |||
June 30, 2022 | 3,940 | (5.8) | 339 | (31.1) | 355 | (34.0) | 192 | (50.6) | |||
June 30, 2021 | 4,183 | 105.8 | 492 | - | 539 | 728.5 | 389 | 993.9 |
(Note) Comprehensive income: | Three months ended June 30, 2022: |
Three months ended June 30, 2021: |
¥ | 158 million | [ | (60.4) %] |
¥ | 400 million | [ | 243.6%] |
Basic earnings | Diluted earnings per | ||||
per share | share | ||||
Three months ended | Yen | Yen | |||
June 30, 2022 | 8.58 | - | |||
June 30, 2021 | 17.37 | - | |||
(2) Consolidated Financial Position | |||||
Total assets | Net assets | Capital adequacy ratio | |||
As of | Million yen | Million yen | % | ||
June 30, 2022 | 35,655 | 32,428 | 90.9 | ||
March 31, 2022 | 36,924 | 32,605 | 88.3 | ||
(Reference) Equity: As of | June 30, 2022: | ¥ | 32,428 million | ||
As of | March 31, 2022: | ¥ | 32,605 million |
2. Dividends
Annual dividends | |||||||||
1st | 2nd | 3rd | Year-end | Total | |||||
quarter-end | quarter-end | quarter-end | |||||||
Yen | Yen | Yen | Yen | Yen | |||||
Fiscal year ended March 31, 2022 | - | 25.00 | - | 15.00 | 40.00 | ||||
Fiscal year ending March 31, 2023 | - | ||||||||
Fiscal year ending March 31, 2023 | 0.00 | - | 0.00 | 0.00 | |||||
(Forecast) | |||||||||
(Note) Revision to the forecast for dividends announced most recently: | No | ||||||||
(Note) Breakdown of the interim dividend for the fiscal year ended March 31, 2022 : | |||||||||
Ordinary dividend | 15 | yen | |||||||
Special dividend | 10 | yen |
3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2023(April 01, 2022 to March 31, 2023)
(% indicates changes from the previous corresponding period.)
Net sales | Operating profit | Ordinary profit | Profit attributable to | Basic earnings | ||||||||
owners of parent | per share | |||||||||||
Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen | ||||
Full year | 13,600 | (18.4) | 1,360 | (13.1) | 1,450 | (9.0) | 970 | (15.4) | 43.31 | |||
(Note) Revision to the financial results forecast announced most recently: | No | |||||||||||
* Notes: | ||||||||||||
(1) Changes in significant subsidiaries during the three months ended June 30, 2022 | ||||||||||||
(changes in specified subsidiaries resulting in changes in scope of consolidation): | No | |||||||||||
New | - | (Company name: | ) | |||||||||
Exclusion: | - | (Company name: | ) | |||||||||
(2) Accounting policies adopted specially for the preparation of quarterly consolidated financial statements: | No |
- Changes in accounting policies, changes in accounting estimates and retrospective restatement
- Changes in accounting policies due to the revision of accounting standards: Yes
- Changes in accounting policies other than 1) above: No
- Changes in accounting estimates: No
- Retrospective restatement: No
- Total number of issued shares (common shares)
- Total number of issued shares at the end of the period (including treasury shares):
June 30, 2022: | 22,547,140 | shares |
March 31, 2022: | 22,547,140 | shares |
2) Total number of treasury shares at the end of the period: | ||
June 30, 2022: | 152,917 | shares |
March 31, 2022: | 152,884 | shares |
3) Average number of shares during the period: | ||
Three months ended June 30, 2022: | 22,394,252 | shares |
Three months ended June 30, 2021: | 22,394,334 | shares |
Quarterly Consolidated Financial Statements
Quarterly Consolidated Balance Sheets
(Million yen) | ||||
As of March 31,2022 | As of June 30,2022 | |||
Assets | ||||
Current assets | ||||
Cash and deposits | 4,807 | 4,569 | ||
Notes and accounts receivable - trade | 4,554 | 3,748 | ||
Securities | 28 | - | ||
Merchandise and finished goods | 1,313 | 1,389 | ||
Work in process | 281 | 291 | ||
Raw materials and supplies | 850 | 763 | ||
Deposits paid to subsidiaries and associates | 19,990 | 19,910 | ||
Other | 123 | 220 | ||
Allowance for doubtful accounts | (0) | (0) | ||
Total current assets | 31,948 | 30,893 | ||
Non-current assets | ||||
Property, plant and equipment | ||||
Buildings and structures, net | 645 | 632 | ||
Machinery, equipment and vehicles, net | 253 | 233 | ||
Land | 2,118 | 2,118 | ||
Leased assets, net | 103 | 98 | ||
Construction in progress | 13 | 13 | ||
Other, net | 72 | 65 | ||
Total property, plant and equipment | 3,207 | 3,162 | ||
Intangible assets | ||||
Software | 92 | 107 | ||
Software in progress | 15 | 4 | ||
Other | 5 | 5 | ||
Total intangible assets | 114 | 118 | ||
Investments and other assets | ||||
Investment securities | 1,308 | 1,243 | ||
Deferred tax assets | 125 | 18 | ||
Other | 219 | 218 | ||
Allowance for doubtful accounts | (0) | (0) | ||
Total investments and other assets | 1,653 | 1,480 | ||
Total non-current assets | 4,975 | 4,761 | ||
Total assets | 36,924 | 35,655 |
3
(Million yen) | ||||
As of March 31,2022 | As of June 30,2022 | |||
Liabilities | ||||
Current liabilities | ||||
Accounts payable - trade | 2,469 | 2,037 | ||
Lease liabilities | 23 | 23 | ||
Income taxes payable | 469 | 27 | ||
Accrued consumption taxes | 107 | 66 | ||
Contract liabilities | 32 | 28 | ||
Provision for bonuses | 363 | 114 | ||
Provision for bonuses for directors (and other | 27 | 6 | ||
officers) | ||||
Other | 360 | 462 | ||
Total current liabilities | 3,853 | 2,767 | ||
Non-current liabilities | ||||
Retirement benefit liability | 1 | 1 | ||
Lease liabilities | 90 | 84 | ||
Long-term guarantee deposits | 372 | 372 | ||
Total non-current liabilities | 465 | 459 | ||
Total liabilities | 4,318 | 3,226 | ||
Net assets | ||||
Shareholders' equity | ||||
Share capital | 4,449 | 4,449 | ||
Capital surplus | 5,378 | 5,378 | ||
Retained earnings | 22,735 | 22,591 | ||
Treasury shares | (100) | (100) | ||
Total shareholders' equity | 32,462 | 32,318 | ||
Accumulated other comprehensive income | ||||
Valuation difference on available-for-sale | 133 | 102 | ||
securities | ||||
Foreign currency translation adjustment | 9 | 6 | ||
Total accumulated other comprehensive income | 142 | 109 | ||
Total net assets | 32,605 | 32,428 | ||
Total liabilities and net assets | 36,924 | 35,655 |
4
Quarterly Consolidated Statements of Income and Comprehensive Income | ||||
Quarterly Consolidated Statements of Income (For the three months) | ||||
(Million yen) | ||||
For the three months | For the three months | |||
ended June 30,2021 | ended June 30,2022 | |||
Net sales | 4,183 | 3,940 | ||
Cost of sales | 2,867 | 2,565 | ||
Gross profit | 1,316 | 1,375 | ||
Selling, general and administrative expenses | 823 | 1,035 | ||
Operating profit | 492 | 339 | ||
Non-operating income | ||||
Interest income | 18 | 17 | ||
Dividend income | 5 | 6 | ||
Share of profit of entities accounted for using equity | 11 | - | ||
method | ||||
Outsourcing service income | 6 | 1 | ||
Gain on valuation of derivatives | 0 | - | ||
Foreign exchange gains | - | 0 | ||
Other | 3 | 4 | ||
Total non-operating income | 46 | 31 | ||
Non-operating expenses | ||||
Interest expenses | 0 | 0 | ||
Share of loss of entities accounted for using equity | - | 13 | ||
method | ||||
Loss on valuation of derivatives | - | 2 | ||
Foreign exchange losses | 0 | - | ||
Total non-operating expenses | 0 | 15 | ||
Ordinary profit | 539 | 355 | ||
Extraordinary income | ||||
Gain on change in equity | 8 | - | ||
Total extraordinary income | 8 | - | ||
Extraordinary losses | ||||
Loss on disposal of non-current assets | 0 | 0 | ||
Loss on valuation of investment securities | - | 34 | ||
Total extraordinary losses | 0 | 34 | ||
Profit before income taxes | 547 | 320 | ||
Income taxes - current | 98 | 8 | ||
Income taxes - deferred | 59 | 120 | ||
Total income taxes | 158 | 128 | ||
Profit | 389 | 192 | ||
Profit attributable to non-controlling interests | - | - | ||
Profit attributable to owners of parent | 389 | 192 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nissui Pharmaceutical Co. Ltd. published this content on 27 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 August 2022 05:13:03 UTC.
